Headquartered in 33 Broadwick Street, London Fiscal year ends December NASDAQ: CMPS compasspathways.com
Compass Pathways plc is a biotechnology company focused on developing new treatment options in mental health care. Its lead product candidate, COMP360, is a proprietary, investigational synthetic psilocybin treatment being evaluated for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). COMP360 has received Breakthrough Therapy designation from the U.S. FDA for TRD and Innovative Licensing and Access Pathway (ILAP) designation in the UK. The company is conducting the world's largest classic psychedelic clinical program in TRD, with two positive Phase 3 trials involving more than 1,000 participants demonstrating rapid onset and durable benefit. Compass is in the process of a rolling NDA submission to the FDA with completion expected in Q4 2026 and a commercial launch anticipated in the first half of 2027, subject to FDA approval and DEA rescheduling. The company is also executing a late-stage PTSD trial. Compass trades on Nasdaq under the ticker CMPS and is transitioning from a clinical-stage to a commercial-stage organization. Updated
Pre-Market Stock Futures: Futures are trading lower as we start off the new week, as oil surges higher amid reports that a U.S. warship was turned back in the Strait of Hormuz,…
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with…
Wednesday's top analyst upgrades and downgrades included AppLovin, Arista Networks, Charles Schwab, First Solar, Global Payments, Halliburton, Monster Beverage, NXP Semiconductor, QuantumScape, Union Pacific and Welltower.
Here is a look of a few of the biggest clinical trial and FDA updates in regards to psychedelics to watch for in 2022.
Here's a quick look at six publicly traded companies developing ways to use psychedelics to treat mental health issues.
Compass Pathways plc is a biotechnology company focused on developing new treatment options in mental health care. Its lead product candidate, COMP360, is a proprietary, investigational synthetic psilocybin treatment being evaluated for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD).
The Wall Street consensus 12-month price target for CMPS is $23.75.
